Recruiting

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

ClinicalTrials.gov IDNCT07606066

PhaseNot Applicable

Enrollment2150

SponsorAstraZeneca

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes

About this study

Interventions

Other: Procedure: assessment — The approximate volume of blood required is 2 mL

Primary outcomes

Patient demographics (Visit 1 (Single day))
Medical and surgical history (Visit 1 (Single day))
Concomitant medication (Visit 1 (Single day))
HbA1c levels (Visit 1 (Single day))

Eligibility information

Inclusion Criteria: * Participants must be ≥ 18 years of age at the time of signing the ICF. * Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World Health Organization or local diagnostic standards, inadequately managed with: 1. Lifestyle management alone, AND/OR 2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF. * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required. * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis. Exclusion Criteria: * Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol). * Diagnosed with Type 1 diabetes mellitus. * Known pregnancy at the time of visit or having the intention to become pregnant.

Study locations

Research Site, Peoria, Arizona 85382 United States
Research Site, Little Rock, Arkansas 72205 United States
Research Site, Lincoln, California 95648 United States
Research Site, Jacksonville, Florida 32256 United States
Research Site, Lake City, Florida 32055 United States
Research Site, Leesburg, Florida 34748 United States
Research Site, Ocoee, Florida 34761 United States
Research Site, Decatur, Georgia 30030 United States
Research Site, Melrose Park, Illinois 60160 United States
Research Site, El Dorado, Kansas 67042 United States

Showing 10 of 76 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.